FDC Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
FDC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
FDC Limited reported its Q1 FY26 results for the quarter ended June 30, 2025. Standalone revenue from operations grew modestly to Rs. 64,228 lakhs from Rs. 62,414 lakhs in Q1 FY25 (about 3% growth). Net profit after tax rose to Rs. 12,219 lakhs from Rs. 11,497 lakhs (about 6% growth), translating to EPS of Rs. 7.51 vs Rs. 7.06. On a consolidated basis, revenue was Rs. 64,841 lakhs and net profit was Rs. 12,335 lakhs. Statutory auditors BSR & Co. LLP issued an unmodified limited review conclusion on both standalone and consolidated results. The company operates in a single segment (Pharmaceuticals) and noted that previous quarterly fair value adjustments mean quarterly figures may not add up to annual totals.
The results show steady but unspectacular growth with stable margins and a clean audit report. For shareholders, this is a neutral-to-slightly-positive outcome—earnings ticked up in line with revenue, no negative surprises, and no governance flags. The stock is unlikely to see major movement on this filing.